A recent clinical trial found that PARP inhibitors can be used to treat advanced male prostate cancer with BRCA1/BRCA2 gene mutations. The relevant results of the study have been published in […]
Inflammation Inflammation is a self-limiting, localized response to any tissue injury or trauma caused by wounding or infection, and is characterized by redness, heat, pain and swelling (rubor, calor, dolor, […]
Olaparib, also known as AZD-2281 or KU-59436, is a small molecule inhibitor of the nuclear enzyme poly (ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to […]